TSI Corporation
This article was originally published in The Gray Sheet
Executive Summary
Plans to reduce staff by approximately 10%. The cuts primarily will affect two of the Worcester, Massachusetts-based company's seven divisions: the Argus preclinical in vivo toxicology lab division and the Health and Sciences Research Inc. clinical testing facility. Administrative staff throughout the firm will also be affected. The reductions respond to an expected 15% revenue decline from the previous quarter, which TSI attributes to "a slowdown in the product development activity in its principal market, the biopharmaceutical industry." The cost-cutting measures also represent the company's consolidation of "certain functions" following seven 1991 and 1992 acquisitions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.